Endpoint
Breast cancer incidence
CAT:outcome/breast-cancer-incidencereported in proportion1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| spironolactone | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Every finding here is a null result.
Measured, no effect detected
1 finding
spironolactone — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“No statistically significant association was observed between spironolactone use and risk of breast cancer (risk ratio [RR], 1.04; 95% CI, 0.86-1.22; certainty of evidence very low).”
Quoted verbatim from Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.. - Study
- meta-analysis
- Population
- Men and women aged 18 years and older ever exposed to spironolactone, pooled from seven observational studies
Effect 1.04 risk ratio, 95% CI 0.86 to 1.22
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.2022PMID:35138351Permalink
How it is measured
Incident breast cancer diagnoses ascertained by cancer registry linkage, pathology report, or medical record review.
Sources cited
1 paper
- Subject
- breast cancer incidence
- Findings
- 1
- Papers
- 1